Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577035 | 0.77 | — | — | |
| SCHEMBL27763112 | 0.77 | — | — | |
| SCHEMBL4124514 | 0.75 | KMT2A (0.44) | — | |
| SCHEMBL20869387 | 0.75 | SLC6A2 (0.34) | — | |
| SCHEMBL15544763 | 0.73 | FDPS (0.31) | FDPS | |
| SCHEMBL15546771 | 0.72 | — | — | |
| SCHEMBL22830547 | 0.71 | CHRM2 (0.38) | FDPS | |
| SCHEMBL27795244 | 0.71 | CHRM2 (0.38) | FDPS | |
| SCHEMBL11562250 | 0.71 | BIRC2 (0.38) | — | |
| SCHEMBL6575454 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288340-B1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2416650-B1 | NANOPARTICLE FORMULATIONS AND USES THEROF | ABRAXIS BIOSCIENCE LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570431-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180363018-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Heterocyclic Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-20180289620-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2018-10-11 | — | — | US | disclosed |
| US-10087478-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a nitrogen-containing compound and uses thereof | NOVOZYMES, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-10041101-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2603594-B1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A BICYCLIC COMPOUND AND USES THEREOF | NOVOZYMES INC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2603598-B1 | COMPOSITIONS COMPRISING A GH61 POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A QUINONE COMPOUND AND USES THEREOF | NOVOZYMES INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| EP-2170913-A1 | PLATINUM (IV) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010014943-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2009-10-22 | — | — | US | disclosed |
| WO-2009126938-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCES, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126401-A1 | COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126175-A1 | COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | PGLS, CEL, PNLIP | FDPS 177/4885 |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | FDPS 1266/4885 |
| US-20180289620-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | FDPS 1266/4885 |
| US-10570431-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | CEL, VIP, CTRC | FDPS 251/4885 |
| US-20180363018-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Heterocyclic Compound And Uses Thereof | CEL, VIP, CTRC | FDPS 251/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | FDPS 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.